Published online before print February 16, 2004, doi: 10.1161/01.CIR.0000117089.99918.5A
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:824-827.)
© 2004 American Heart Association, Inc.
Brief Rapid Communications |
Predictors of Outcome After Alcohol Septal Ablation Therapy in Patients With Hypertrophic Obstructive Cardiomyopathy
From the Department of Medicine (S.M.C.), Section of Cardiovascular Medicine, University of Wisconsin, Madison; and Department of Medicine (N.M.L., J.F., W.H.S., S.F.N.), Section of Cardiology, Baylor College of Medicine, Houston, Tex.
Correspondence and reprint requests to Sherif F. Nagueh, MD, 6550 Fannin, SM 1256, Houston, TX 77030. E-mail sherifn{at}bcm.tmc.edu
Received October 24, 2003; revision received December 19, 2003; accepted December 30, 2003.
Background— Alcohol septal ablation (ASA) therapy results in clinical and hemodynamic improvement in patients with hypertrophic obstructive cardiomyopathy. However, a subset remains symptomatic afterward, requiring additional procedures. We sought to examine the determinants of an unsatisfactory outcome, defined as unchanged symptoms with <50% reduction of baseline left ventricular outflow tract (LVOT) gradient.
Methods and Results— Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who underwent ASA, 39 had an unsatisfactory outcome after the first procedure. Patients with an unsatisfactory outcome had a higher baseline LVOT gradient, fewer septal arteries injected with ethanol, lower peak creatine kinase (CK), smaller septal area opacified by contrast echocardiography, and higher residual gradient in the catheterization laboratory after ASA (all P<0.05). Symptoms, septal thickness, mitral regurgitation severity, and ventricular function were not determinants of outcome. On multiple logistic regression, LVOT gradient reduction after ASA in the catheterization laboratory to 
25 mm Hg (OR, 5.5; P=0.01) and peak CK <1300 U/L (OR, 2.5; P=0.04) were the independent predictors of an unsatisfactory outcome.
Conclusions— The residual LVOT gradient in the catheterization laboratory and peak CK leak after ASA are the independent predictors of ASA outcome.
Key Words: ablation • cardiomyopathy • hypertrophy • alcohol
This article has been cited by other articles:
 |
|
 |
|
  W A Jaber, E H Yang, R A Nishimura, P Sorajja, C S Rihal, A Elesber, E Eeckhout, and A Lerman Immediate improvement in coronary flow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy Heart, April 1, 2009; 95(7): 564 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Cuoco, W. H. Spencer III, V. L. Fernandes, C. D. Nielsen, S. Nagueh, J. L. Sturdivant, R. B. Leman, J. M. Wharton, and M. R. Gold Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death After Alcohol Septal Ablation of Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., November 18, 2008; 52(21): 1718 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sorajja, U. Valeti, R. A. Nishimura, S. R. Ommen, C. S. Rihal, B. J. Gersh, D. O. Hodge, H. V. Schaff, and D. R. Holmes Jr Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy Circulation, July 8, 2008; 118(2): 131 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Togni, M. Billinger, S. Cook, and O. M. Hess Septal myectomy: cut, coil, or boil? Eur. Heart J., February 1, 2008; 29(3): 296 - 298. [Full Text] [PDF]
|
|
|
|
|
|
E. Durand, E. Mousseaux, P. Coste, R. Pilliere, O. Dubourg, L. Trinquart, G. Chatellier, A. Hagege, M. Desnos, and A. Lafont Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up Eur. Heart J., February 1, 2008; 29(3): 348 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. ElBardissi, J. A. Dearani, R. A. Nishimura, S. R. Ommen, J. M. Stulak, and H. V. Schaff Septal Myectomy After Previous Septal Artery Ablation in Hypertrophic Cardiomyopathy Mayo Clin. Proc., December 1, 2007; 82(12): 1516 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Nagueh, J. M. Buergler, M. A. Quinones, W. H. Spencer III, and G. M. Lawrie Outcome of Surgical Myectomy After Unsuccessful Alcohol Septal Ablation for the Treatment of Patients With Hypertrophic Obstructive Cardiomyopathy J. Am. Coll. Cardiol., August 21, 2007; 50(8): 795 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy Circulation, July 10, 2007; 116(2): 196 - 206. [Full Text] [PDF]
|
|
|
|
|
|
A L Baggish, R N Smith, I Palacios, G J Vlahakes, D M Yoerger, M H Picard, P A Lowry, I-k Jang, and M A Fifer Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy Heart, December 1, 2006; 92(12): 1773 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J Knight Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart, September 1, 2006; 92(9): 1339 - 1344. [Full Text] [PDF]
|
|
|
|
|
|
C. van der Lee, F. J. ten Cate, M. L. Geleijnse, M. J. Kofflard, C. Pedone, L. A. van Herwerden, E. Biagini, W. B. Vletter, and P. W. Serruys Percutaneous Versus Surgical Treatment for Patients With Hypertrophic Obstructive Cardiomyopathy and Enlarged Anterior Mitral Valve Leaflets Circulation, July 26, 2005; 112(4): 482 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron Surgery for Hypertrophic Obstructive Cardiomyopathy: Alive and Quite Well Circulation, April 26, 2005; 111(16): 2016 - 2018. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, J. A. Dearani, S. R. Ommen, M. S. Maron, H. V. Schaff, B. J. Gersh, and R. A. Nishimura The case for surgery in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2044 - 2053. [Abstract] [Full Text] [PDF]
|
|